Breaking News

Pillar5 Pharma Expands Operations

August 23, 2013

Receives $1M from Eastern Ontario Development Fund

Pillar5 Pharma, Inc. has received $1 million from the Eastern Ontario Development Fund (EODF) to expand production at its Arnprior manufacturing facility, creating 56 new jobs and retaining 94 more in the community.
 
With support from EODF, Pillar5 will increase its operations by installing two new, advanced production lines for the manufacturing and packaging of eye care products. This expansion will better position the company to pursue new markets, both at home and abroad.
 
Dr. Eric Hoskins, Minister of Economic Development, Trade and Employment, said, “We are proud to be supporting job creation right here in eastern Ontario. This investment will help Pillar5 become a leader in the production of eye care products while expanding their markets and bringing new jobs and prosperity to the community of Arnprior.”
 
Kevin Rampton, chief executive officer of Pillar5 Pharma, commented, “We are thankful for the support from the Ontario government. This expansion means we can offer our customers more solutions for their pharmaceutical outsourcing needs. It also gives us greater capacity to increase production and explore new markets.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important